Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05550337 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
A Phase 3 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 807
- Enrollment target
NCT05550337: Completed Phase 3 study, sponsored by Teva Pharmaceuticals USA.
NCT05550337 is a Phase 3 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 807 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05550337, a Phase 3 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 807 participants
- Enrollment target
Study Summary
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
Interventions
- DRUG Placebo
- DRUG Trifarotene 0.005 % Topical Cream
- DRUG AKLIEF®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 807 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05550337
The ClinicalTrials.gov registry entry for NCT05550337 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 807 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05550337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05550337 about?
NCT05550337 is a clinical study titled "Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris". To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
What is the current status of trial NCT05550337?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 807 participants. The study started on 2022-09-19. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT05550337?
The interventions under investigation include: Placebo (DRUG), Trifarotene 0.005 % Topical Cream (DRUG), AKLIEF® (DRUG).
Who is sponsoring clinical trial NCT05550337?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.